James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Monsanto (MON) Earnings Preview: Will Soy Save the Day on Wednesday?

As bad as things have been for MON stock of late, the Monsanto earnings news due Wednesday could make them even worse.

Gold Prices Set to Soar in Q2

Gold prices, as well as silver prices, are positioned to move to higher levels.

Why Southern Copper (SCCO), Tesla Motors (TSLA) and OvaScience (OVAS) Are 3 of Today’s Worst Stocks

From smaller-than-expected drug studies to violent protests, these are the catalysts that sent today's losers plunging Friday.

The BlackBerry Earnings Report Still Doesn’t Make BBRY Stock a Buy

BlackBerry has successfully shrunk its way to success. Unfortunately, the price of BBRY stock hasn't adjusted to the new company size yet.

Investing in Alzheimer’s Disease Drugs Just Became Complicated

Everything pharmaceutical companies thought they knew about Alzheimer's disease may (or may not) be wrong.